The Federal Trade Commission (FTC) on Tuesday settled with CVS Health Corp. (NYSE:CVS) subsidiary Caremark, requiring the pharmacy benefit manager to overhaul key business practices aimed at lowering prescription drug costs, expanding transparency, and improving access to pharmacy services.
The agency estimates the agreement could generate up to $8.5 billion in consumer savings over the next decade, with an additional $4.5 billion in savings through point-of-sale rebates.
Read Next
Trump Admin Rescinds $10 Billion Child Care Funding Freeze for Five Democratic-Led States
The funding freeze on child care subsidies and social services has been lifted by the U.S. Department of Health and Human Services.
